BioSpace News Archive

The increasing prevalence of various chronic diseases such as diabetes that results in kidney disorders is a key factor aiding in expansion of the global end stage renal disease market during the forecast period between 2020 to 2030.

Evotec SE announced that the U.S. Department of Defense awarded its Seattle, Washington-based subsidiary, Just - Evotec Biologics, Inc., an agreement worth $28.6 million for the production of monoclonal antibodies for use in the development of a treatment and/or prophylaxis for COVID-19.

Hansa Biopharma will publish its Year-End report 2020 at 8:00 CET on February 4, 2021. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 14:00 CET/2:00pm EST.

ADVANZ PHARMA Corp. Limited announced that its board of directors has reached an agreement on the terms of a cash offer, to be made by a subsidiary of Nordic Capital, pursuant to which Nordic Capital will acquire the entire issued and to-be-issued limited voting share capital of ADVANZ PHARMA.

Smith+Nephew, the global medical technology business, is pleased to announce a new publication showing that its PICO Single Use Negative Pressure Wound Therapy System significantly reduced the odds of surgical site infections by 63%*, the odds of seroma by 77%†, and the odds of dehiscence by 30%‡.

Osteopore and Maastricht University Medical Centre has developed a first-of-its-kind, bioresorbable bone implant solution that prevents leg amputations in patients with severe lower leg fractures

With flavors driving youth vaping and youth tobacco use overall, ‘State of Tobacco Control’ 2021 adds new grade to end sale of all flavored tobacco

Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that its Board of Directors has appointed Nabil Shabshab as Inogen’s President and Chief Executive Officer (“CEO”), effective February 8, 2021

SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel potential treatments for multiple therapeutic areas, announced today that the Immune Tolerance group leader, Shinu John, PhD, will present new preclinical data from the company’s Tolerizing Antigen Carriers (SQZ™ TACs) platform in an invited talk at the Antigen-Specific Immune Tolerance (ASIT) Digital Summit taking place January 26, 2021

IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2020 fourth quarter financial results before the market opens on Thursday, February 4 th . IRADIMED management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results and to answer questions.